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CLINICAL STUDIES CONDUCTED OVER THE TOTAL PRODUCT LIFE CYCLE OF 
HIGH-RISK THERAPEUTIC MEDICAL DEVICES RECEIVING US FOOD AND DRUG 
ADMINISTRATION PREMARKET APPROVAL IN 2010 AND 2011.  
 
Vinay K. Rathi, Harlan M. Krumholz, Frederick A. Masoudi, and Joseph S. Ross.  
 
Center for Outcomes Research and Evaluation, Yale University School of Medicine and 
Yale-New Haven Hospital, New Haven, Connecticut. 
 
The US Food and Drug Administration (FDA) approves high-risk medical devices, 
those that support or sustain human life or present potential unreasonable risk to patients, via 
the Premarket Approval (PMA) pathway. In recent years, the FDA has begun shifting 
premarket evidentiary requirements to the postmarket period as part of a broader effort to 
continually evaluate device safety and effectiveness throughout the total product life cycle. 
We therefore sought to characterize the clinical evidence generated for high-risk therapeutic 
devices over the total product life cycle. In October 2014, we identified all clinical studies of 
high-risk therapeutic devices receiving initial market approval via the PMA pathway in 2010 
and 2011 through ClinicalTrials.gov and publicly available FDA documents. Studies were 
characterized by type (pivotal, studies that served as the basis of FDA approval; FDA-
required postapproval studies [PAS]; or manufacturer/investigator-initiated); premarket or 
postmarket; status (completed, ongoing, or terminated/unknown); and design features, 
	
	
including enrollment, comparator, and longest duration of primary effectiveness end point 
follow-up. We identified 286 clinical studies of the 28 high-risk therapeutic devices which 
received initial marketing approval via the PMA pathway in 2010 and 2011: 82 (28.7%) 
premarket and 204 (71.3%) postmarket, among which there were 52 (18.2%) nonpivotal 
premarket studies, 30 (10.5%) pivotal premarket studies, 33 (11.5%) FDA-required PAS, and 
171 (59.8%) manufacturer/investigator-initiated postmarket studies. Six of 33 (18.2%) PAS 
and 20 of 171 (11.7%) manufacturer/investigator-initiated postmarket studies were reported 
as completed. No postmarket studies were identified for 5 (17.9%) devices; 3 or fewer were 
identified for 13 (46.4%) devices overall. Median enrollment was 65 patients (interquartile 
range [IQR], 25-111), 241 patients (IQR, 147-415), 222 patients (IQR, 119-640), and 250 
patients (IQR, 60-800) for nonpivotal premarket, pivotal, FDA-required PAS, and 
manufacturer/investigator-initiated postmarket studies, respectively. Approximately half of 
all studies used no comparator (pivotal: 13/30 [43.3%]; completed postmarket: 16/26 
[61.5%]; ongoing postmarket: 70/153 [45.8%]). Median duration of primary effectiveness 
end point follow-up was 3.0 months (IQR, 3.0-12.0), 9.0 months (IQR, 0.3-12.0), and 12.0 
months (IQR, 7.0-24.0) for pivotal, completed postmarket, and ongoing postmarket studies, 
respectively. In conclusion, among high-risk therapeutic devices approved via the FDA PMA 
pathway, total product life cycle evidence generation varied in both the number and quality 
of premarket and postmarket studies, with approximately 13% of initiated postmarket studies 
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Medical Device Risk Classification & Regulatory Pathways 
 
The United States Food and Drug Administration (FDA) primarily regulates medical 
devices through 1 of 3 pathways – the 510(k) Premarket Notification (510[k]), Humanitarian 
Device Exemption (HDE), and Premarket Approval (PMA) pathways.1-3 The pathway 
through which each device is regulated depends on the risk associated with use, the intended 
patient population, and the presence of similar previously marketed devices. First established 
under the 1976 Medical Device Amendments Act, the FDA risk classification system for 
devices categorizes products into 1 of 3 tiers based on the level of regulatory control 
necessary to assure device safety and effectiveness (Class I – low risk, Class II – moderate 
risk, and Class III – high-risk; Table 1).4 Roughly two-thirds of all devices regulated by the 
FDA are classified as low-risk; these devices (e.g., dental floss and walking canes) are 
subject to general regulatory controls such as good manufacturing practices and largely 
exempt from FDA premarket review.5 Approximately 30% of devices are classified as 
moderate-risk; these devices (e.g., electrocardiographs and tympanostomy tubes) are 
regulated via the 510(k) pathway and require both general and special (e.g., performance 
standards) regulatory controls for marketing. High-risk devices – those that support or sustain 
human life, are of substantial importance in preventing illness, or present potential, 
unreasonable risk to patients – comprise a small fraction of all devices. These devices (e.g., 
coronary stents and hip implants) are regulated either via the PMA or HDE pathways, the 
latter of which is reserved for devices used in the diagnosis or treatment of uncommon 
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Premarket Clinical Evidence Requirements & Generation 
 
 Device manufacturers must satisfy FDA premarket evidence requirements prior to 
marketing moderate- and high-risk devices. To obtain marketing clearance for a new device 
via the 510(k) pathway, manufacturers must demonstrate that the device is “substantially 
equivalent” in materials, purpose, and mechanism of action to a previously marketed 
“predicate” device (or components thereof);3,6 fewer than 10% of 510(k) submissions to the 
FDA require clinical evidence for clearance.3 In recent years, the 510(k) pathway has come 
under increased scrutiny in the wake of high-profile device recalls (e.g., the Depuy ASR 
metal-on-metal hip implant, which was withdrawn from the market in 2010 after the National 
Joint Registry for England and Wales reported a 5-year revision rate of 13%);7-9 in 2011, the 
Institute of Medicine issued a report recommending that the 510(k) pathway be replaced by 
an entirely new regulatory framework for moderate-risk devices.5,10 Criticism of the 510(k) 
pathway centers around 5 major issues. First, certain high-risk devices are still permitted to 
enter the market via the less stringent 510(k) pathway as a result of temporary exemptions 
dating back to the 1976 Medical Device Amendments Act.11-14 Second, manufacturers may 
obtain marketing clearance on the basis of substantial equivalence to unsafe predicates, 
including permanently recalled devices.15 Third, manufacturers may claim unproven new 




characteristics and indications for use.11,16,17 Fourth, manufacturers may market poorly 
understood technologies through the process of “predicate creep,” whereby multiple cycles of 
substantial equivalence determinations result in a new device that is quite dissimilar from the 
original predicate.15,16 Fifth, the FDA has permitted manufacturers to market chimeric new 
devices on the basis of substantial equivalence to the individual characteristics of several 
distinctly different predicates (i.e., “split” predicates).7 In response to these criticisms, the 
FDA has committed to transitioning all high-risk devices away from the 510(k) pathway,11,12 
improving the quality of publicly available summaries of scientific data supporting each 
device,18 and adopting less permissive standards of substantial equivalence (e.g., prohibiting 
split predicates).3 
 In contrast to the 510(k) pathway, the PMA pathway is intended to regulate high-risk 
devices and requires premarket clinical evidence providing reasonable assurance of device 
safety and effectiveness as a condition of approval;1 in addition, manufacturers must submit 
supplemental PMA applications prior to implementing any post-approval changes affecting 
device safety or effectiveness (e.g., design modifications or labeling changes expanding 
indications for use).19 By statute, the FDA may only require manufacturers to generate the 
“least burdensome” clinical data necessary to establish device safety and effectiveness.20 
Though these data requirements are more stringent than those of European regulators,21,22 
recent studies have criticized the strength of clinical evidence supporting FDA approval of 
high-risk devices.23-25 Whereas most novel pharmaceuticals are approved on the basis of 2 
large double-blind randomized controlled trials demonstrating independent evidence of 
efficacy,26 FDA premarket evaluation of device safety and effectiveness typically focuses on 




endpoints.23,24,27 In addition, the external validity of these studies is often limited by small 
enrollment numbers and inadequate representation of important subpopulations, including 
women, racial minorities, and children.24,25  
Calls for more robust premarket clinical evidence have grown louder following recent 
device failures, such as fractures (Medtronic Sprint Fidelis) and insulation breakdowns (St. 
Jude Riata) of widely-used cardioverter-defibrillator leads.28,29 Unlike pharmaceuticals, many 
high-risk devices are implantable and cannot simply be discontinued when concerns arise, 
leaving patients and physicians to weigh the risks of re-operation against leaving potentially 
harmful foreign bodies in place.27,30 Furthermore, high-risk devices often undergo extensive 
postmarket changes via supplemental PMA applications,31-33 which are typically approved 
without supporting clinical evidence19 and may be subject to less stringent review than 
intended by the FDA (e.g., labeling changes expanding indications for use approved via 
review tracks requiring only pre-clinical data).32 In a recent study, implantable cardiac 
electronic devices were found to have accumulated nearly 30 labeling or design changes over 
their market life, with approximately one-fifth of major design changes supported by new 
clinical data.33 These incremental changes may nonetheless pose unanticipated danger to 
patients (e.g., otogenic meningitis caused by the addition of an electrode positioner to 
Advanced Bionics CII cochlear implant),34 reduce therapeutic benefit (e.g., spontaneous 
shutdown of the best-selling and recently recalled Cochlear Nucleus CI500),35 and ultimately 
lead devices used in practice to differ substantially from those originally described in 
published studies.31  
Premarket evidentiary standards are lower for high-risk devices approved via the 




marketing; instead, manufacturers must provide clinical evidence of safety and "probable 
benefit" to obtain FDA approval.2 Prior work has accordingly found HDE approvals to be 
supported by less rigorous clinical studies,36 leading patients to be implanted with devices 
that were subsequently proven dangerous (e.g. the Wingspan neurovascular stent, which was 
found to cause an increased risk of stroke and death in implanted patients).37 Nonetheless, the 
FDA and Congress have recently proposed regulatory reforms that would lower premarket 
evidence requirements for high-risk devices in an effort to expedite patient access to new 
therapies and promote technological innovation.38,39  
Postmarket Clinical Evidence Requirements & Generation 
 
 To complement premarket understanding of safety and effectiveness, the FDA has 
become increasingly committed to devices throughout their “total product life cycle,”40 an 
approach that involves ongoing study and reevaluation for as long as devices remain in use.41 
As part of this approach, the FDA conducts both passive and active postmarket data 
collection following device approval. The FDA conducts passive data collection through 3 
distinct reporting programs, known as Mandatory Medical Device Reporting, MedWatch, 
and the Medical Product Safety Network.42 Mandatory Medical Device Reporting requires 
manufacturers, importers, and user facilities (i.e., hospitals, nursing homes, and outpatient 
treatment and diagnostic centers) to report all deaths and serious adverse events for which a 
device is suspected or known to have caused or contributed to patient harm.43 MedWatch is a 
voluntary reporting program enabling consumers and healthcare professionals to alert the 
FDA about all manner of safety issues, ranging from product quality problems and potential 
harms to serious adverse events and death.44 The Medical Product Safety Network consists of 




concerns beyond the scope of Mandatory Medical Device Reporting (e.g., product use errors 
and close calls).45  
While these passive surveillance measures may help detect safety signals and assess 
real-world device performance (e.g., hydrocephalus shunt valve failures due to rough 
handling),46 their utility is greatly limited by the variable quality and inadequate number of 
reports,47-49 which are often delayed in their submission by manufacturers and review by the 
FDA (e.g., deaths caused by vagus nerve stimulators reported several years later).47,48 These 
unstandardized reports often lack critical information necessary to identify devices, 
understand adverse events, and exclude unrelated factors (e.g., procedural errors) as the cause 
of harm.48 This critical information is altogether unavailable for reports never submitted as a 
result of poor end-user engagement; only 6% of adverse event reports originate from 
consumers and healthcare professionals48 who may be impeded by fear of litigation, failure to 
connect devices to outcomes, and insufficient knowledge or support to fulfill reporting 
obligations.47,48,50 The pervasive problem of underreporting is compounded by the fact that 
manufacturers determine whether adverse events are linked to devices and need not report 
unrelated incidents, which may incentivize mischaracterization of negative outcomes.47,48,51 
Both underreporting and lack of information on the number of devices in use prevent 
calculation of product-specific adverse event rates through passive surveillance, thereby 
decreasing the strength of safety signals relative to noise and precluding direct comparison 
between devices.48,49 
 In addition to monitoring passively collected reports, the FDA can actively address 
clinical questions by requiring manufacturers to complete postmarket studies. The FDA is 




Studies and Post-Approval Studies (PAS).52,53 522 Postmarket Surveillance Studies (522 
studies) may be ordered at any point during the market life of a device, and are most often 
initiated in response to safety concerns emerging in the course of real-world clinical practice 
(e.g., infection transmission via reprocessed duodenoscopes).54 The FDA may order 522 
studies up to 3 years in duration for both 510(k) and PMA-regulated devices, provided that 
the device meets any of the following 4 criteria: (1) failure would be reasonably likely to 
have adverse health consequences, (2) expected to have significant use in pediatric 
populations, (3) intended to be implanted in the body for more than 1 year, or (4) intended to 
be a life-sustaining or life-supporting device operated outside a user facility.55 In practice, 
nearly 95% these studies have examined devices cleared via the 510(k) pathway (i.e., on the 
basis of substantial equivalence), with more than three-quarters of these studies ordered for 
metal-on-metal hip implants (cited above) and surgical mesh used in urogynecological 
procedures (linked to adverse events such as dyspareunia and vaginal erosion and pain).56,57 
Although the FDA has ordered roughly 400 postmarket surveillance studies to date,56 there 
are concerns that these studies may have limited potential to inform regulatory and clinical 
decision making as a result of delays by manufacturers avoiding unfavorable findings, lack of 
harmonization to allow cross-product comparison, and inadequate follow-up to assess long-
term outcomes.58 
 In contrast to 522 studies, the FDA may order PAS as a condition of approval for 
devices regulated via the PMA (including supplemental applications) and HDE pathways.53 
These studies are not subject to statutory limits on duration and typically designed to 
complement premarket understanding of device safety and effectiveness with information 




indications for use, and subgroup safety.56 These FDA-required studies serve as important 
opportunities to assess device performance, and approximately half of PMA and HDE 
devices approved since 1995 have been subject to PAS,59 three quarters of which involved 
prospective clinical data collection (as opposed to laboratory or retrospective studies).56 
However, PAS may often be small,60 delayed,37,60 or not generalizable to real-world 
populations of use (including women and children).25,59 Moreover, only one-quarter of PAS 
required by the FDA between 2005 and 2011 were completed.60 Nonetheless, PAS may have 
significant implications for clinical practice, as study findings have prompted manufacturers 
to remove unsafe devices from the market and update device labeling with critical 
information (e.g., no dose-response for a depression treatment), though the effect of such 
labeling changes on treatment decisions is unknown.60 
 Beyond FDA-required postmarket studies, complementary sources of evidence may 
be generated through studies initiated by manufacturers or independent investigators. A 
recent survey suggests that manufacturers may primarily conduct postmarket clinical studies 
to comply with regulatory requirements.61 Alternatively, these companies may also choose to 
invest in postmarket studies as a means to broaden applications of use and clinical acceptance 
of a product.62 As the FDA adopts more flexible premarket evidence standards to expedite 
patient access to new technologies,38,63,64 the information generated from both FDA-required 
and manufacturer/investigator-initiated postmarket studies will become increasingly 
important in guiding regulatory and clinical decisions.   




Statement of Purpose 
 Our objective was to characterize the clinical studies of high-risk therapeutic devices 
initially approved via the FDA PMA pathway between 2010 and 2011 to better understand 
the amount and quality of evidence generated over the total product life cycle. Prior to 
conducting this study, we put forth the following specific hypotheses: 
 
1. The FDA will have approved virtually all high-risk therapeutic devices receiving 
initial Premarket Approval in 2010 and 2011 on the basis of a single pivotal clinical 
study; additional premarket clinical evidence generated through feasibility studies of 
these devices will be of limited strength due to small enrollment numbers. 
2. The number of postmarket studies per device will vary widely; little postmarket 
evidence will have been generated for a significant proportion of devices. 
3. Manufacturers and independent investigators will initiate a significant proportion of 
postmarket studies without FDA requirement; many of these studies will assess 
devices in clinical contexts beyond those specified by FDA-approved indications.  
4. Postmarket device studies will be of higher quality compared to premarket studies, 
particularly with respect to enrollment number, comparator, and duration of primary 
endpoint follow-up. 
The specific aim of the thesis was twofold: (1) to promote critical evaluation of the clinical 
evidence available to inform medical decision-making about high-risk medical devices by 
patients and physicians and (2) to inform ongoing legislative and regulatory efforts seeking 
to balance pre- and postmarket evidentiary requirements for high-risk medical devices and 








We constructed a sample of high-risk therapeutic devices initially receiving US 
marketing approval via the FDA PMA pathway between January 1, 2010 and December 31, 
2011 using the publicly accessible PMA database (Figure 1).65 We selected this sample 
period in order to ensure that the majority of relevant trials were registered on 
ClinicalTrials.gov – an online public clinical trials registry maintained by the National 
Library of Medicine – in compliance with the 2007 FDA Amendments Act.66 We used 
information on device type listed within the FDA database to exclude all nontherapeutic (i.e., 
diagnostic) devices,67 including detection kits, molecular assays, and imaging machines. 
Based on information within the publicly available FDA Summary of Safety and 
Effectiveness Data (SSED, hereafter referred to as the FDA Summary) linked to each 
original PMA application,68 we further excluded therapeutic devices that were previously 
marketed in the United States for another indication. 
Device Characteristics 
 
Using information within the PMA database, we classified each device in our sample 
by the following characteristics: approval year, medical specialty area,67 review type 
(normal/expedited), implantable designation (yes/no), and life-saving designation (yes/no). 
We also characterized their recall history by searching the FDA’s online Medical Device 
Recalls Database using PMA application numbers and recording the highest recall class for 





Identification of Clinical Studies 
 
We primarily identified clinical studies using ClinicalTrials.gov (Figure 2); with the 
exception of small feasibility studies, the 2007 FDA Amendments Act required that all 
device studies ongoing as of December 2007 be registered on ClinicalTrials.gov.66 For each 
device in our cohort, we initially searched ClinicalTrials.gov for the device trade name 
specified at the time of PMA application, any previously marketed trade names appearing in 
the FDA Summary, and any newly marketed trade names appearing in the PMA database. 
We included all resulting studies describing use of the device under these trade names, 
excluding duplicates. Using the FDA Summary for each device, we then searched for any 
trade names of its component devices as applicable. If the component was originally 
approved as part of the PMA application, we included all newly identified studies describing 
its use. If the component was not approved as part of the PMA application, we included any 
newly identified studies describing its use as adjunctive to a comparable device that we could 
not exclude as being the device of interest within our sample.  
After searching for clinical studies of interest based on trade names, we then screened 
further using combinations of manufacturer names and device descriptors as our search 
terms. We first used information provided in the FDA Summary, the FDA website,70,71 and 
manufacturer website to determine relevant device descriptors and abbreviations thereof for 
each device (e.g., “bronchial radiofrequency” and “bronchial RF”), leveraging descriptors in 
the generic technology name to differentiate our device of interest within the manufacturer’s 
product line when necessary (e.g., “everolimus platinum stent” as opposed to “everolimus 
stent” for Boston Scientific). We also searched the PMA database to identify all 




mergers, acquisitions, and rebranding. For each device, we then searched ClinicalTrials.gov 
for combinations of manufacturer name(s) and device descriptors. We included newly 
identified resulting studies that mentioned relevant combinations of manufacturer name(s) 
and device descriptors, provided that the study examined a technologically equivalent, 
unnamed device that was both attributable to the correct manufacturer by study description or 
sponsorship and conducted in a setting consistent with the marketing history outlined in the 
FDA Summary. For devices produced by smaller manufacturers or with device descriptors 
either highly specific in name or unique to a single manufacturer, we additionally searched 
ClinicalTrials.gov for these manufacturer names and device descriptors alone. We included 
newly identified studies resulting from these searches that described use of a comparable 
device that we could not exclude as being the device of interest within our sample. 
All searches were performed by VKR in October 2014. The principal investigator 
(J.S.R.) reviewed all potentially relevant studies derived from this multi-step search 
algorithm along with another investigator (V.K.R.) to determine appropriateness for 
inclusion. We excluded studies with an enrollment status of “Not yet recruiting,” 
“Suspended,” or “Withdrawn.” If an identified study compared two or more devices in our 
sample, the study was counted once for each device. 
Following our search of ClinicalTrials.gov, we then reviewed all feasibility and 
pivotal studies described in FDA Summaries and PAS listed within the FDA PAS database;72 
no 522 postmarket surveillance studies were ordered for devices in our sample.55 Pivotal 
studies are those which serve as the primary basis for the FDA’s premarket evaluation of 
device safety and effectiveness.73 Studies described solely within FDA documents were 




conducted in support of the PMA application, we considered each named sub-study with 
FDA-required follow-up of the premarket cohort as a separate PAS.  
Clinical Study Features 
 
For all identified studies, we abstracted the following information from 
ClinicalTrials.gov and/or FDA documents (Box 1): enrollment number, study status 
(completed, ongoing, terminated/unknown), primary completion date (i.e., final data 
collection for primary outcomes), and study type (pivotal study, FDA-required PAS, or 
manufacturer/investigator-initiated study). 
Box 1. Coding of Premarket & Postmarket Clinical Study Enrollment, Status, and Type 
  
Enrollment: Study enrollment size was recorded as specified in the “Enrollment” field on 
ClinicalTrials.gov or described in FDA approval letters mandating post-approval studies. 
Study enrollment size for pivotal studies identified through FDA Summaries was recorded as 
the number of randomized patients. For feasibility studies identified through FDA 
Summaries, the number of patients receiving the study intervention was recorded as the 
enrollment size. 
 
Study status: For studies identified through ClinicalTrials.gov, study status was recorded as 
most recently specified on the study page; studies listed as “Completed” were categorized as 
completed, studies listed as “Recruiting,” “Enrolling by invitation,” or “Active, not 
enrolling” were categorized as ongoing, and studies listed as “Terminated” or “Unknown” 
were categorized as terminated/unknown. We considered all pivotal and feasibility studies 
identified through FDA Summaries to be completed. We determined the study status of 
FDA-required post-approval studies using the “Study Progress” field within the FDA Post-
Approval Studies database; studies were categorized as “Ongoing” if study progress was 
reported as “Progress Adequate” or “Progress Inadequate,” “Unknown” if progress was 
reported as “Study Pending,” and “Completed” if reported as such. 
   
Primary completion date: For studies identified through ClinicalTrials.gov, primary 
completion date was recorded as specified in the “(Estimated) Primary Completion Date” 
field. In rare instances, no primary completion date was reported on ClinicalTrials.gov, and 
we used information reported in the “Completion Date” field instead. If neither field was 
populated, we estimated the primary completion date by adding the duration of longest 
follow-up for the primary outcome measure to the date of last verification by the study 
sponsor. For pivotal studies identified through FDA Summaries, we used the date of last data 
collection as reported. For feasibility studies identified through FDA Summaries, we 




estimate the primary completion date by adding the duration of longest follow-up to the date 
of final patient enrollment. In rare instances, we were unable to locate a published report of 
the feasibility study within the literature, and instead used a search of the Web to identify the 
dates of news items reporting on the results of these studies. Studies with a primary 
completion date prior to initial FDA marketing approval were categorized as premarket; all 
other studies were categorized as postmarket. 
 
Study type: Studies identified through ClinicalTrials.gov were determined to be pivotal or 
post-approval studies if described as such within the “Official Title,” “Brief Description,” or 
“Detailed Description” fields. We further identified pivotal and post-approval studies among 
those identified through ClinicalTrials.gov by comparing reported enrollment size, setting, 
and design features to study descriptions provided within FDA resources. All other studies 
were considered to be manufacturer/investigator-initiated.  
  
We then abstracted additional information on study features for all pivotal premarket, 
completed postmarket, and ongoing postmarket studies; non-pivotal premarket and 
terminated/unknown studies were excluded from further analysis because the information 
available was often insufficient for characterization. We collected the following additional 
study features (Box 2): funder, centers, location, registry design, blinding, study groups, 
comparator, and randomization. 
Box 2. Coding of Pivotal Premarket & Completed/Ongoing Postmarket Clinical Study 
Features 
 
Funder: Coded as “Industry,” “Other,” or “Mixed” (i.e., both industry and outside funding 
sources) based on ClinicalTrials.gov downloadable output. Pivotal and post-approval studies 
identified through FDA resources were considered to be “Industry” funded. 
 
Centers: Coded as “Single-center” or “Multi-center.” Studies explicitly described as single-
center or with only one study center listed were considered to be “Single-center.” All other 
studies were considered to be “Multi-center.” 
 
Locations: Coded as “All US,” “Some US,” or “No US” based on the description and/or 
listing of study center locations. All multi-center studies with at least one US location listed 
were considered to be “Some US.” Studies with no stated location were considered to be 
“Some US.”  
  
Registry: Coded as “Registry” or “Non-registry.” A clinical study was considered to be a 





Blinding: Coded as “Open label”, “Single-blind”, or “Double-blind.” Studies described as 
being blinded to an objective outcomes assessor or without explicit mention of blinding were 
considered to be “Double-blind.” Studies described as being blinded to either patient or 
investigator without mention of the other were considered to be “Single-blind.” 
Observational, single-group, and registry studies were considered to be “Open label.” All 
other studies were classified as reported. 
 
Study Groups: Coded as “Single-group” or “Multi-group.” Studies explicitly described as 
single-group, with only one group listed, or in which all groups received the same treatment 
were considered to be “Single-group.” All other studies were considered to be “Multi-group.” 
 
Comparators: Coded as “None”, “Active comparator,” or “Placebo/Sham.” Clinical studies 
with standard of care as the control group were considered to have an “Active Comparator.” 
Single-group studies were considered to have “None.” All other studies were classified as 
reported. 
 
Randomization: Coded as “Randomized”, “Non-randomized”, or “N/A.” Single-group 
studies were classified as “N/A” because randomization is not possible in such a design. 
Studies not explicitly described as being randomized were considered to be “Non-
randomized.” All other studies were classified as reported. 
 
Using clinical experience and judgment, members of the study team (V.K.R. and 
J.S.R.) additionally determined whether the indications for device use in each ongoing and 
completed postmarket study (both FDA-required PAS and manufacturer/investigator-
initiated studies) differed from the original FDA-approved indication as explicitly described 
in the corresponding FDA Summary. This determination (original or different) was made 
based on information within the postmarket study description and inclusion/exclusion 
criteria, which outlined the conditions and population for which the device was used. If there 
was insufficient information to make a determination, we categorized the indication as not 
differing by default. Of note, we did not consider studies using the Edwards Sapien 
transcatheter heart valve in high-risk surgical patients to have a differing indication; although 
the device was originally cleared for the treatment of inoperable patients, the same pivotal 




data pertaining to clinical study features was abstracted by VKR; all characterizations of 
indications were confirmed by JSR, with conflicts resolved by consensus. Several 
representative examples of differing and non-differing indications are provided with 
supporting rationale (Box 3). 
Box 3. Characterization of Indications for Device Use in Postmarket Studies 
 
Indications Differing from Original FDA-Approved Indication 
 
Different Example #1 
 
Original FDA indication: “The Arctic Front Cardiac CryoAblation Catheter and 
CryoConsole (Arctic Front® Cryocatheter System) are indicated for the treatment of drug 
refractory recurrent symptomatic paroxysmal atrial fibrillation.” 
 
ClinicalTrials.gov study description: “The purpose of this study is to evaluate the 
effectiveness of Pulmonary Vein Isolation (PVI) performed with the Arctic Front™ Advance 
Cardiac CryoAblation Catheter System as first-line therapy in comparison with 
antiarrhythmic drugs (AAD) in patients with paroxysmal atrial fibrillation (AF).” 
 
Supporting rationale: Cryoballoon ablation was originally FDA-approved for the indication 
of treating drug-refractory patients, but here is studied as first-line treatment. 
 
Different Example #2 
 
Original FDA indication: “The Edwards SAPIEN Transcatheter Heart Valve (THV), model 
9000TFX, sizes 23mm and 26mm, is indicated for transfemoral delivery in patients with 
severe symptomatic native aortic valve stenosis who have been determined by a cardiac 
surgeon to be inoperable for open aortic valve replacement and in whom existing co-
morbidities would not preclude the expected benefit from correction of the aortic stenosis.” 
 
ClinicalTrials.gov study description: “The purpose of this registry is to retrospectively and 
prospectively obtain clinical data in consecutively treated patients, in order to demonstrate 
that the commercially available Edwards SAPIEN Valve with the RF3 delivery system is a 
safe and effective treatment for patients with pulmonary regurgitation or stenosis.” 
 
Supporting rationale: Study assesses artificial heart valve implantation in the pulmonic 
position, whereas device is originally FDA-approved for the indication of implantation in the 
aortic position. 
 





Original FDA indication: “Belotero® Balance is indicated for injection into the mid-to-deep 
dermis for correction of moderate- to-severe facial wrinkles and folds such as nasolabial 
folds.” 
 
ClinicalTrials.gov study description: “Inclusion criteria: (1) Active stage TO [thyroid 
opthalmopathy] as determined by symptom onset of under 9 months AND (2) Upper eyelid 
retraction of 1 mm or greater in one or both eyes AND (3) Complaints of either significant 
ocular symptoms (despite appropriate use of ocular lubricants), or cosmetic deformity 
associated with the eyelid retraction” 
 
Supporting rationale: Study assesses dermal filler for treatment of thyroid eye disease, 
whereas the filler is originally FDA-approved for the indication of treating facial wrinkles. 
 
Different Example #4 
 
Original FDA indication: “The PROMUS Element Plus Everolimus-Eluting Platinum 
Chromium Coronary Stent System is indicated for improving luminal diameter in patients 
with symptomatic heart disease due to de novo lesions in native coronary arteries >2.25 mm 
to <4.00 mm in diameter in lesions <28 mm in - length.” 
 
ClinicalTrials.gov study description: “Inclusion criteria: long lesion (lesion length >30mm 
by visual estimation) or in stent restenosis of bare metal stent or everolimus-eluting stent.” 
 
Supporting rationale: Study includes patients with stent restenosis and patients with lesion 
length ≥ 28 mm, but the stent was originally FDA approved for the indication of treating 
symptomatic heart disease caused by de novo lesions < 28 mm in length. Lesions 28-34 mm 
in length were approved as an indication for treatment via supplemental pre-market 
application based on clinical evidence supporting a different size of the stent. 
 
Indications Consistent with Original FDA-Approved Indication 
 
Original Example #1 
 
Original FDA indication: “The Alair ® Bronchial Thermoplasty System is indicated for the 
treatment of severe persistent asthma in patients 18 years and older whose asthma is not well 
controlled with inhaled corticosteroids and long acting beta agonists.” 
 
ClinicalTrials.gov study description: “Inclusion Criteria: (1) Patient with severe persistent 
asthma uncontrolled found in stable [condition] for at least 3 weeks AND (2) Patient 
receiving regular treatment with inhaled corticosteroids (beclomethason[e] > 1000 mcg or 
equivalent) and LABA (salmeterol >= 100 mcg or equivalent) AND (3) AQLQ score < 6.25 
AND (4) FEV1 >= 60% predicted AND (5) Patients not smoking for at least one year ” 
 
Supporting rationale: Patients eligible for inclusion must have uncontrolled asthma despite 





Original Example #2 
 
Original FDA indication: “The CeramaxTM Ceramic Total Hip System is indicated for 
noncemented use in skeletally mature individuals undergoing primary total hip replacement 
surgery for rehabilitation of hips damaged as a result of noninflammatory degenerative joint 
disease (NIDJD) or any of its composite diagnoses of osteoarthritis, avascular necrosis, and 
post-traumatic arthritis.” 
 
ClinicalTrials.gov study description: “Inclusion Criteria: (1) Post-operative clinical 
evaluation judged successful using Harris Hip Scoring system (HHS > 90) AND (2) Body 
weight less than 270 lbs AND (3) No evidence of post-operative hip subluxation or 
dislocation AND (4) Do not walk with detectable limp AND (5) Be able to actively abduct 
their operated hip against gravity without falling AND (6) Must be willing to sign Informed 
Consent and Health Insurance Portability and Accountability (HIPAA) forms. Exclusion 
Criteria: (1) Pregnant, lactating females or females not using reliable form of birth control 
AND (2) Patients that do not meet study requirements AND (3) Patients unwilling to sign 
Informed Consent or HIPAA forms” 
 
Supporting rationale: Insufficient information is provided to determine the indications for 
hip prosthesis implantation (i.e., inflammatory vs. non-inflammatory joint disease) among 
study patients.  
 
Original Example #3 
 
Original FDA indication: “The Pipeline Embolization Device is indicated for the 
endovascular treatment of adults (22 years of age or older) with large or giant wide-necked 
intracranial aneurysms (IAs) in the internal carotid artery from the petrous to the superior 
hypophyseal segments.” 
 
ClinicalTrials.gov study description: “Inclusion Criteria: (1) Subjects who are age 22 or 
higher AND (2) IA of at least 10 mm in maximum distension along the internal carotid artery 
between the petrous and superior hypophyseal segments” 
 
Supporting rationale: Inclusion criteria specify use of the device in the same patient 
population (age 22 years or older) and disease state (large IA within specific anterior 
circulation anatomical bounds) as the original FDA indication.  
 
Original Example #4 
 
Original FDA indication: “Gel-One ® is indicated for the treatment of pain in osteoarthritis 
(OA) of the knee in patients who have failed to respond adequately to non-pharmacologic 
therapy, non-steroidal anti-inflammatory drugs (NSAIDs) or analgesics, e.g., 
acetaminophen.” 
 
ClinicalTrials.gov study description: “Inclusion Criteria: (1) Have knee pain AND (2) Grade 




Exclusion Criteria: (1) BMI greater than 35 kg/m2 AND (2) Received an intra-articular 
hyaluronic acid injection for the treatment of OA of the knee within 6 months prior to 
screening AND (3) Had a joint replacement of the target knee” 
 
Supporting rationale: Inclusion criteria specify device use for the indication of knee pain 
secondary to osteoarthritis. Insufficient information is provided to definitively determine 
whether the device is to be used as first- or second-line treatment (i.e., whether patients have 
failed non-pharmacologic and pharmacologic therapies prior to enrollment). 
 
Clinical Study Primary Effectiveness Endpoints 
 
 We identified and characterized all primary effectiveness endpoints assessed in 
pivotal premarket, completed postmarket, and ongoing postmarket studies. Primary endpoints 
of pivotal and postmarket studies identified through ClinicalTrials.gov were recorded as 
reported in the “Current Primary Outcome Measures” field on each study page. Additionally, 
we searched the FDA Summary for each pivotal study registered on ClinicalTrials.gov to 
identify any additional primary endpoints discussed in the study description. We classified 
endpoints describing adverse events or other sequelae related to previous treatment with the 
study device (e.g., blood metal ion level measurement following metal-on-ceramic hip 
implantation) as safety endpoints. We classified endpoints describing the state of the medical 
condition for which the patient received treatment with the study device (e.g., number of 
severe respiratory exacerbations observed in asthma patients undergoing bronchial 
thermoplasty) as effectiveness endpoints. In the event that a composite endpoint described 
elements of both, we classified the endpoint as an effectiveness endpoint.  Mortality was 
considered an effectiveness endpoint unless specifically designated otherwise; whenever an 
endpoint was explicitly classified on ClinicalTrials.gov, we considered it to be as such.  
For pivotal studies identified through FDA Summaries, we classified endpoints as 




it to be an effectiveness endpoint. If no primary endpoint was explicitly named, we 
designated the endpoints discussed within the “Effectiveness Endpoints” and “Safety 
Endpoints” sections as primary endpoints; in these select instances, a maximum of 3 
endpoints were named in per section. We considered the primary endpoints of PAS providing 
follow-up of previously enrolled cohorts to be the same as the original study, unless 
explicitly specified otherwise by information within the Post-Approval Studies database.  
For each primary effectiveness endpoint, we recorded the duration of longest follow-
up (using the pre-specified duration for ongoing studies). Primary effectiveness endpoints 
were then classified as “clinical outcomes,” “clinical scales,” or “surrogate markers of 
disease” based on an established framework and a recent Institute of Medicine report.26,74 
“Clinical outcomes” measure patient survival or function (e.g., overall survival, 50-foot walk 
test, or freedom from reoperation). “Clinical scales” represent rubrics for the quantification 
of subjective patient-reported symptoms (e.g., Harris Hip Score, best-corrected visual acuity, 
or New York Heart Association Functional Classification Status). “Surrogate markers of 
disease” represent biomarkers expected to predict clinical status (e.g., aortic insufficiency as 
measured by echocardiogram, maximum observed everolimus blood concentration, or 
reduction in smooth muscle surface area as objectified on bronchial biopsies). Endpoints 
classified as “Clinical outcomes” and “Clinical scales” were grouped together and classified 
as “Clinical outcomes” for purposes of analysis. Composite endpoints with both clinical and 
surrogate components were considered to be “Clinical outcomes.” All data pertaining to 
primary endpoints was abstracted by VKR; all characterizations of endpoints were confirmed 






We used descriptive statistics to characterize our high-risk therapeutic device sample. We 
calculated median enrollment numbers for non-pivotal premarket, pivotal premarket, FDA-
required PAS, and manufacturer/investigator-initiated postmarket studies, and used the 
Kruskal-Wallis test to assess for a difference between these 4 study types. We then used 
descriptive statistics to characterize all other features of pivotal premarket, completed 
postmarket, and ongoing postmarket clinical studies; FDA-required PAS and 
manufacturer/investigator-initiated postmarket studies were categorized together to provide a 
holistic perspective of completed and ongoing postmarket evidence generation. Analyses of 
primary effectiveness endpoints were conducted at the endpoint-level because some studies 
had multiple primary effectiveness endpoints and some studies had only safety endpoints. 
We then used χ2 and Kruskal-Wallis tests as appropriate to examine for differences in 
features and primary effectiveness endpoints between these 3 study types. Analyses were 
performed using Microsoft Excel 2011 and JMP version 10.0 (SAS Institute Inc.). All 
statistical tests were 2-tailed, and we used a type 1 error rate of 0.05 in testing enrollment 
number. To account for multiple comparisons, we used type I error rates of 0.006 and 0.0125 
in testing all other study features (9 comparisons) and endpoint characteristics (4 







Between 2010 and 2011, the FDA granted initial marketing approval for 28 high-risk 
therapeutic devices via the PMA pathway: 21 (75.0%) were implantable and 9 (32.1%) were 
life-sustaining (Table 1). About half (n=15; 53.6%) were for cardiovascular conditions. Ten 
(35.7%) were recalled at least once, with one (3.6%) undergoing a Class I recall (highest-
risk: reasonable probability of serious health problems or death) and one (3.6%) voluntarily 
withdrawn from market.  
Table 2. High-Risk Therapeutic Devices Receiving Initial Marketing Approval via the FDA 
Premarket Approval Pathway in 2010 and 2011 
 
 
  No. (%) 
Approval Year 
   2010 12 (42.9) 
  2011 16 (57.1) 
Medical Specialty Area 
   Anesthesiology  2 (7.1) 
  Cardiovascular 
      Coronary stent 3 (10.7) 
     Non-coronary stent 12 (42.9) 
  Ear, Nose, and Throat 2 (7.1) 
  General and Plastic Surgery 1 (3.6) 




  Ophthalmology 3 (10.7) 
  Orthopedics 3 (10.7) 
Priority Review 
   Yes 6 (21.4) 
  No 22 (78.6) 
ImplantableA 
   Yes 21 (75.0) 
  No 7 (25.0) 
Life-SustainingA 
   Yes 9 (32.1) 
  No 19 (67.9) 
Highest Recall ClassB 
   Class I 1 (3.6) 
  Class II 8 (28.6) 
  Class III 1 (3.6) 
  Withdrawn 1 (3.6) 
  No Recall 17 (60.7) 
Notes: FDA=Food and Drug Administration. 
A Determined based on the product code given for each device. 
B The FDA classifies recalls into 3 categories based on the relative degree of health hazard 
presented by the device being recalled: Class I – reasonable probability of serious adverse 
health consequences or death; Class II – reasonable probability of temporary or medically 
reversible adverse health consequences, or remote probability of serious adverse health 
consequences or death; and Class III – low probability of adverse health consequences.  





We identified 286 clinical studies of these 28 high-risk therapeutic medical devices 
(Figure 3): 52 (18.2%) non-pivotal premarket studies, 30 (10.5%) pivotal premarket studies, 
33 (11.5%) FDA-required PAS, and 171 (59.8%) manufacturer/investigator-initiated 
postmarket studies. A total of 44 (84.6%) non-pivotal premarket studies were reported as 
completed, as were all 30 (100.0%) pivotal premarket studies (Table 2). In contrast, 6 
(18.2%) FDA-required PAS and 20 (11.7%) manufacturer/investigator-initiated postmarket 
studies were reported as completed, with 23 (69.7%) and 130 (76.0%) reported as ongoing, 
respectively; 2 (6.1%) FDA-required PAS were pending.  
 The median number of non-pivotal premarket studies per device was 1 (Interquartile 
Range [IQR], 0-2), and 26 (92.9%) devices received FDA approval on the basis of a single 
pivotal premarket study. At least 1 PAS was required by the FDA for 19 (67.9%) devices; 
nearly all (n=29; 87.9%) were ordered as a condition of approval for the original PMA 
application, while the remainder (n=4; 12.1%) were ordered following market introduction as 
a condition of approval for a supplemental PMA application. The median number of 
manufacturer/investigator-initiated postmarket studies was 3 (IQR, 1-6). We were unable to 
identify any postmarket studies (including completed, ongoing, or terminated/unknown 
studies) for 5 (17.9%) devices; 3 or fewer studies were identified for 13 (46.4%) devices 
overall.  
Median enrollment was 65 (Interquartile Range [IQR], 25-111), 241 (IQR, 147-415), 
222 (IQR, 119-640), and 250 (IQR, 60-800) patients for non-pivotal premarket, pivotal, 
FDA-required PAS, and manufacturer/investigator-initiated postmarket studies, respectively. 
Median enrollment was lower among completed FDA-required PAS and 




43-252], respectively) than among ongoing postmarket studies (300 [IQR, 120-1115] and 
300 [IQR, 60-1011], respectively).  
Although only 3 of 28 (10.7%) devices in our sample were coronary stents, 75 of 179 
(41.8%) completed and ongoing postmarket studies (including FDA-required PAS) examined 
these devices. Among these coronary stent studies, median enrollment was 572 patients 
(IQR, 237-2000), whereas median enrollment was 135 patients (IQR, 50-326) for the 104 
studies of all other devices. Focusing on the 10 devices in our sample that were recalled at 
least once, 67 of 104 (64.4%) ‘non-coronary stent’ completed and ongoing postmarket 
studies examined these devices; median study enrollment was 130 patients (IQR, 50-318) for 
recalled devices, 165 patients (IQR, 40-346) for non-recalled devices. 
Table 3. Number of and Enrollment in Clinical Studies Examining High-Risk Therapeutic 
Devices Receiving Initial Marketing Approval via the FDA Premarket Approval Pathway in 

















Overall, No. (%) 52 (18.2) 30 (10.5) 33 (11.5) 171 (59.8) 
No. (%) by Study Status 
  Completed 44 (84.6) 30 (100.0) 6 (18.2) 20 (11.7) 
  Ongoing 3 (6.8) 0 (0) 23 (69.7) 130 (76.0) 
  
Terminated/Unknown 




Median No. Studies 
per Device (IQR) 
1 (0-2) 1 (1-1) 1 (0-2) 3 (1-6) 
Median No. Studies per Device (IQR) by Study Status 
  Completed 1 (0-2) 1 (1-1) 0 (0-0) 0 (0-1) 
  Ongoing 0 (0-0) 0 (0-0) 1 (0-1) 2 (0-5) 
  
Terminated/Unknown 









Median Enrollment (IQR) by Study Status 












78 (57-104) N/A 136 (69-210) 156 (55-1150) 
Notes: FDA=Food and Drug Administration; IQR=Interquartile Range. 
Pivotal Premarket & Completed/Ongoing Postmarket Clinical Study Features 
 
Study features were characterized for 209 studies: 30 (14.4%) pivotal premarket 
studies, 26 (12.4%) completed postmarket studies, and 153 (73.2%) ongoing postmarket 
studies (Figure 2). Whereas all pivotal studies were solely funded by industry (30 of 30 
[100.0%)] and virtually all were multi-center (28 of 30 [93.3%]) and enrolled U.S. patients 




26 [65.4%]; ongoing: 91 of 153 [59.5%]), were multi-center (completed: 18 of 26 [69.2%], 
ongoing: 92 of 153 [60.1%]), and enrolled U.S. patients (completed: 15 of 26 [57.7%], 
ongoing: 63 of 153 [41.2%]) (p values ≤ 0.002; Table 3). Pivotal and postmarket study 
design features were otherwise broadly similar, as approximately 10% were designated 
registries, roughly three-quarters were unblinded, and nearly half were single-group and thus 
had no comparator. Among multi-group studies, more than three-quarters used active 
comparators and were randomized. Finally, nearly half of all postmarket studies (83 of 179 
[46.4%]) explicitly described examining devices for different indications than those 
originally approved by the FDA (completed: 9 of 26 [34.6%], ongoing: 74 of 153 [48.4%]). 
 Table 4. Characteristics of Clinical Studies Examining High-Risk Therapeutic Devices 
Receiving Initial Marketing Approval via the FDA Premarket Approval Pathway in 2010 and 
2011, by Study Status and Type 
 
 




(n = 30) 
Completed  
Postmarket  
(n = 26) 
Ongoing  
Postmarket  
(n = 153) 
Funder, No. (%) 
   
< 0.001 
  Industry 30 (100.0) 16 (61.5) 57 (37.3) 
 
  Mixed 0 (0.0) 1 (3.8) 34 (22.2) 
 
  Other 0 (0.0) 9 (34.6) 62 (40.5) 
 
Centers, No. (%) 
   
0.002 
  Multi-center 28 (93.3) 18 (69.2) 92 (60.1) 
 





Locations, No. (%) 
   
< 0.001 
  All US 15 (50.0) 9 (34.6) 38 (24.8) 
 
  Some US 14 (46.7) 6 (23.1) 25 (16.3) 
 
  No US 1 (3.3) 11 (42.3) 90 (58.8) 
 
Registry, No. (%) 
   
0.75 
  No 28 (93.3) 23 (88.5) 136 (88.9) 
 
  Yes 2 (6.7) 3 (11.5) 17 (11.1) 
 
Blinding, No. (%)    0.06 
  Double-blind 6 (20.0) 2 (7.7) 8 (5.2)  
  Single-blind 5 (16.7) 2 (7.7) 25 (16.3)  
  Open label 19 (63.3) 22 (84.6) 120 (78.4)  
Study Groups, No. (%) 
  
0.29 
  Multiple-groups 17 (56.7) 10 (38.5) 83 (54.2) 
 
  Single-group 13 (43.3) 16 (61.5) 70 (45.8) 
 
Comparator, No. (%) 
  
0.01A 
  Active comparator 13 (43.3) 9 (34.6) 80 (52.3) 
 
  Placebo/Sham 4 (13.3) 1 (3.8) 3 (2.0)  
  None 13 (43.3) 16 (61.5) 70 (45.8) 
 
Randomization, No. (%) 
   
0.19A 
  N/A (Single-group) 13 (43.3) 16 (61.5) 70 (45.8) 
 
  Non-randomized 0 (0.0) 2 (7.7) 13 (8.5) 
 
  Randomized 17 (56.7) 8 (30.8) 70 (45.8) 
 
Indication, No. (%) 





  Original N/A 17 (65.4) 79 (51.6) 
 
  Different N/A 9 (34.6) 74 (48.4) 
 
Notes: FDA= Food and Drug Administration; IQR=Interquartile Range. P values represent 
statistical comparisons across study type and status for each clinical study characteristic. 
A Excluding single-group studies. 
B Excluding pivotal studies. 
Pivotal Premarket & Completed/Ongoing Postmarket Clinical Study Primary Effectiveness 
Endpoints 
 
We identified 226 primary effectiveness endpoints among these 209 studies: 44 
(19.5%) endpoints among 30 pivotal studies, 27 (11.9%) endpoints among 26 completed 
postmarket studies, and 155 (68.6%) endpoints among 153 ongoing postmarket studies 
(Figure 2). Nearly 80% (35 of 44) of pivotal study endpoints were clinical outcomes, in 
contrast to 57.1% of postmarket study endpoints (completed: 14 of 27 [51.9%], ongoing: 90 
of 155 [58.1%]; p=0.02) (Table 4). Median duration of endpoint follow-up was 3.0 months 
(IQR, 3.0-12.0) for pivotal studies, 9.0 months (IQR, 0.3-12.0) for completed postmarket 
studies, and 12.0 months (IQR, 7.0-24.0) for ongoing postmarket studies (p=0.002). 
However, we found no difference in median duration of endpoint follow-up for implantable 
device studies (pivotal: 12.0 months [IQR, 4.0-12.0], completed postmarket: 10.5 months 
[IQR, 0.3-21.0], ongoing postmarket: 12.0 months [IQR, 8.0-24.0]; p=0.07). 
Table 5. Primary Effectiveness Endpoints of Clinical Studies Examining High-Risk 
Therapeutic Devices Receiving Initial Marketing Approval via the FDA Premarket Approval 


















(n = 44) 
Endpoints 
(n = 27) 
Endpoints 
(n = 155) 
Endpoint Type, No. (%) 
     Clinical Outcome 35 (79.5) 14 (51.9) 90 (58.1) 0.02 
  Surrogate Marker 9 (20.5) 13 (48.1) 65 (41.9) 
 Median Duration of 
Longest Follow-Up 
(months) (IQR) 
    
Overall 
3.0 (3.0 - 
12.0) 
9.0 (0.3 - 
12.0) 
12.0 (7.0 - 24.0) 0.002 
  Non-ImplantableA 
1.5 (0.0 - 
12.0) 
6.0 (0.0 - 
12.0) 
12.0 (6.0 - 24.0) 0.01 
  ImplantableA 
12.0 (4.0 - 
12.0) 
10.5 (0.3 - 
21.0) 
12.0 (8.0 - 24.0) 0.07 
Notes: FDA=Food and Drug Administration; IQR=Interquartile Range. P values represent 
statistical comparisons across study type and status for endpoint type and median duration of 
longest follow-up. 





Study Findings & Prior Literature 
 
Our characterization of the clinical studies examining high-risk therapeutic medical 
devices initially approved via the FDA PMA pathway between 2010 and 2011 demonstrates 
that the amount and quality of evidence generated over the total product life cycle varies 
widely. Some devices are currently being evaluated through ongoing studies that, if 
completed, will provide evidence on clinical outcomes for large numbers of patients with 
planned follow-up of a year or longer. However, most devices have been or will be evaluated 
through only a few studies, which often focus on surrogate markers of disease in small 
numbers of patients followed over short time periods of time, and study indications that 
differ from the original FDA-approved indication.  
Premarket clinical studies of high-risk therapeutic devices were limited in number 
and quality. Nearly all devices were cleared on the basis of 2 studies: 1 non-pivotal and 1 
pivotal study. Non-pivotal studies are typically conducted to assess device feasibility, 
enrolling a limited number of patients to examine device performance and guide premarket 
development (e.g., design modifications) and clinical use (e.g., anatomical restrictions).75 
Non-pivotal studies may also include internationally-based studies initiated prior to FDA 
approval; in our study, all incomplete non-pivotal premarket studies were internationally-
based. In addition, to support market approval, the FDA requires at least one pivotal study 
providing substantial evidence of device safety and effectiveness. We found that pivotal 
studies generally enrolled fewer than 300 patients and were often designed without blinding, 
comparators, or primary endpoint follow-up exceeding 1 year. Our results are consistent with 




cardiovascular diseases, rare conditions, and patients who are children or have unmet medical 
needs,24,25,36,63 with the exception of primary endpoint selection; whereas prior work found 
the majority of primary endpoints in pivotal studies to be surrogate markers of disease,24,25 
we identified nearly 80% as clinical outcomes for devices in our sample. Nonetheless, our 
findings confirm that premarket studies provide limited data to address important clinical 
questions that often arise after approval, including those related to long-term device 
performance, new indications or iterations, and safety and effectiveness in real-world 
populations.32,33,36,76  
Prior studies have not examined total product life cycle evidence generation for high-
risk therapeutic devices, instead focusing solely on the FDA PAS program or orthopedic 
prostheses, which often receive market clearance via the 510(k) regulatory pathway intended 
for moderate-risk devices.60,77 We found that postmarket studies, like premarket studies, were 
often small, un-blinded, and without comparators. In addition, postmarket studies – including 
those examining implantable devices – were also generally limited to 1 year of primary 
endpoint follow-up, and nearly half focused on surrogate markers of disease. However, 
approximately 13% of identified postmarket studies were completed between 3 and 5 years 
after FDA approval; three-quarters of postmarket studies remained ongoing. Postmarket 
evidence may be generated from ongoing observational studies and registries before 
completing primary effectiveness endpoint follow-up, as well as afterwards from longer-term 
follow-up of safety endpoints. However, the potential for this postmarket evidence to inform 
practice remains unclear, even under the presumption that all ongoing studies will be 
completed, given that clinicians often rapidly adopt new devices after market introduction31,78 




selective outcome reporting.79-81 Furthermore, it is unclear how this evidence will inform 
regulatory decisions, if at all, such as whether to recall a product. Interestingly, completed 
and ongoing postmarket studies examining recalled and non-recalled devices were similar in 
size.  
Clinical & Policy Implications 
 
The FDA has adopted a total product life cycle approach to device evaluation with the 
understanding that, “[a]t the time of device approval, certain safety and effectiveness 
questions may not be fully resolved [...] because controlled clinical studies do not fully 
represent the benefit-risk profile of a device when used in real-world clinical practice.”64 
Although the FDA may not require a PAS for every newly approved device, the agency often 
requires a postmarket study to complement premarket understanding of device safety and 
effectiveness. However, by law, the FDA may only require the “least burdensome” 
postmarket data necessary to address unresolved clinical questions about devices,38 limiting 
its capacity to mandate additional studies for the purpose of generating evidence to inform 
regulatory and clinical decision-making. Furthermore, the FDA has not imposed penalties 
against manufacturers failing to comply with postmarket study requirements mandated 
through its PAS program.60 Our findings of limited premarket evidence generation and few 
FDA-required postmarket studies highlight the need for continued study, either through 
manufacturer-initiated or investigator-initiated studies, to advance postmarket understanding 
of device safety and effectiveness. Approximately 85% of the postmarket studies we 
identified were not initiated in response to FDA requirements, and 40% were conducted 
without manufacturer support. To ensure generation of additional robust, objective evidence 




taking on a more principal role in supporting postmarket research, as they have done for 
several commonly used pharmaceutical products. For instance, the Patient-Centered 
Outcomes Research Institute – newly established under the 2010 Patient Protection and 
Affordable Care Act – could further prioritize funding of large, pragmatic comparative 
effectiveness studies designed to empower patients and physicians with real-world data on 
high-risk devices and their therapeutic alternatives.82 
The “right” number and “appropriate” design of premarket and postmarket studies for 
high-risk therapeutic devices should vary based on expected benefit and risk, therapeutic 
alternatives, and anticipated challenges of widespread use, including physician learning 
curves and facility expertise. For any given device, conducting numerous large studies with 
long periods of follow-up may not be a feasible or efficient use of resources. However, 
pending legislative efforts will only further reduce premarket evidence requirements for 
medical devices in order to expedite patient access to new technologies.83 Although the FDA 
has begun developing postmarket safety surveillance methods, used primarily for 
pharmaceuticals and biologics, that leverage routinely collected electronic health information 
through a distributed data model under its Mini-Sentinel initiative,84 the validity of these 
methods remains uncertain and this approach cannot be used for surveillance of medical 
devices until there is widespread adoption of unique device identifiers.85 Moreover, safety 
surveillance efforts have uncertain applications for generation of comparative effectiveness 
evidence or insights into long-term effectiveness of medical devices. Postmarket assessments 
of both medical device safety and effectiveness in real-world practice through clinical trials, 
registries, and analysis of health systems data will continue to provide complimentary 




FDA has actively engaged in efforts to strengthen our national network of device registries 
and develop powerful accompanying analytical tools through the Medical Device 
Epidemiology Network and High-Performance Integrated Visual Environment initiatives,86-88 
though much work remains to realize the promise of big data in analyzing health outcomes 
across disparate sources.   
Limitations 
 
Our study has several limitations that deserve consideration. First, we may not have 
identified all clinical studies of devices in our sample despite the inclusive nature of our 
search algorithm, and our findings may thus under-represent the clinical evidence generated. 
This is more likely true of non-pivotal premarket clinical studies, as these could have taken 
place prior to the ClinicalTrials.gov registration requirements that took effect in late 2007. 
Nevertheless, all pivotal studies were identified, and these studies represent the most robust 
evidence available during premarket evaluation. Conversely, by including all studies 
registered on ClinicalTrials.gov, our study may over-represent the clinical evidence 
generated, particularly in the postmarket period; approximately one-third of clinical trials 
remain unpublished even years after study completion and only one-fifth of completed trials 
registered on ClinicalTrials.gov report their results,89,90 such that the results of many studies 
we identified may never be disseminated to inform clinical practice. Second, we cannot 
account for postmarket studies not registered on ClinicalTrials.gov, such as chart reviews or 
case-studies, though the strength of evidence derived from these studies is often limited. In 
addition, internationally-based studies may also be less likely to be registered on 
ClinicalTrials.gov, although more than half of the postmarket studies we identified were 




of medical devices are required to be registered on ClinicalTrials.gov under FDAAA and 
comprised nearly half of the postmarket studies we identified. However, non-product-specific 
registries (i.e., disease registries) were unlikely to have been identified, and may importantly 
contribute to device evaluation over the total product life cycle.7,91,92 Third, our analysis was 
cross-sectional and our search was completed in October 2014, allowing between 3 and 5 
years for studies to be initiated and completed after FDA approval. It is likely that there will 
be additional clinical studies examining these devices, and some of the studies we identified 
as ongoing will be completed or already have been completed. However, we expect that most 
major postmarket clinical studies of devices are likely to be initiated within 5 years of 
approval given their relatively short market life, and our findings therefore likely reflect the 
best evidence available and anticipated to inform clinical practice. Finally, our study was 
focused on evidence generated for high-risk therapeutic devices receiving PMA approval. 
Our findings do not apply to devices receiving market clearance via the 510(k) or 
Humanitarian Device Exemption regulatory pathways, which are used less frequently for 
high-risk devices and subject to lower evidentiary standards, nor to diagnostic devices 
receiving PMA approval; of note, the FDA will no longer allow manufacturers to obtain 
marketing clearance for high-risk devices via the 510(k) pathway in the near future,11,12 
further enhancing the generalizability of our findings.  
Conclusions 
 
Among high-risk therapeutic devices approved via the FDA PMA pathway between 
2010 and 2011, total product life cycle evidence generation varied in both the number and 
quality of premarket and postmarket studies, with approximately 13% of initiated postmarket 
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Figures, Titles, and Legends 
Figure 1. Sample Construction of High-Risk Therapeutic Devices Receiving Initial 
Marketing Approval via the FDA Premarket Approval Pathway in 2010 and 2011 
 

























Figure 2. Identification of Clinical Studies Examining High-Risk Therapeutic Devices 
Receiving Initial Marketing Approval via the FDA Premarket Approval Pathway in 2010 and 
2011 
 
Legend: “Unknown” includes studies of both terminated and unknown status. The 26 
“Completed Postmarket” studies were comprised of 6 completed FDA-required PAS and 20 
completed manufacturer/investigator-initiated postmarket studies (i.e., “Non-FDA-Required 
Postmarket Studies”). Similarly, the 153 “Ongoing Postmarket” studies were comprised of 
23 ongoing FDA-required PAS and 130 ongoing manufacturer/investigator-initiated 









































































Figure 3. Evidence Generation for High-Risk Therapeutic Devices Receiving Initial 
Marketing Approval via the FDA Premarket Approval Pathway in 2010 and 2011, including 
premarket non-pivotal and pivotal studies and postmarket FDA-required Post-Approval 
studies and manufacturer/investigator-initiated studies. 
 
Legend: Each vertical bar represents the device Premarket Approval approval date, organized 
from oldest (bottom) to newest (top). For each device, pre- and postmarket studies appear to 
the left and right of the vertical bar, respectively. A single large registry study involving two 
coronary stents in our cohort was excluded from the plot, as were the 3 premarket non-
pivotal studies reported as “Ongoing.” Abbreviation: FDA, Food and Drug Administration. 
 
